Dust Mite Allergy clinical trials
The registry lists 45 studies for Dust Mite Allergy across more than 10 countries. 6 are recruiting or about to start. 31 of them are mainly about Dust Mite Allergy (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-17.
Get an email when these change. Save the Dust Mite Allergy studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Inmunotek S.L. (5) · Johann Wolfgang Goethe University Hospital (3) · Stallergenes Greer (3) · Universitaire Ziekenhuizen KU Leuven (2) · Cytos Biotechnology AG (2) · University of North Carolina, Chapel Hill (2) · Circassia Limited (2) · Ecarf Institute GmbH (2)
What is being tested here
Drugs under test in Dust Mite Allergy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Nov 2026Dupilumab Effects Against Aeroallergen Challenge · The University of Texas Health Science Center at San Antonio
- May 2027Identification of B Regulatory Cells by Flow Cytometry · Hull University Teaching Hospitals NHS Trust
Who these studies take
Of the 3 Dust Mite Allergy studies recruiting now, 1 (33%) set no upper age limit and 2 (67%) stop at 75 or younger. 2 (67%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (33%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 3 (100%) | 3 (100%) |
| 40 | 3 (100%) | 3 (100%) |
| 50 | 3 (100%) | 3 (100%) |
| 65 | 3 (100%) | 3 (100%) |
| 75 | 1 (33%) | 1 (33%) |
| 85 | 1 (33%) | 1 (33%) |
Across all 45 studies, recruiting or not: 89% stop at 75 or younger and 89% at 65; 29% take children; 0% are for women only and 0% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 45 of 45. search them.
- Identification of B Regulatory Cells by Flow CytometryRecruitingNCT068765061 country
- Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or DfRecruitingNCT07348302Phase 34 countries
- Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With TezepelumabNot yet recruitingNCT07013123Phase 3
- Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDMRecruitingNCT05395689Phase 31 country
- Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen ExtractNot yet recruitingNCT05641272Phase 2/31 country
- Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/RhinoconjunctivitisNot yet recruitingNCT05400811Phase 31 country
- Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic RhinitisCompletedNCT07157462Not applicable1 country
- Dupilumab Effects Against Aeroallergen ChallengeActive, not recruitingNCT05720325Phase 21 country
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)CompletedNCT06920771Phase 35 countries
- BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)CompletedNCT075963031 country
- Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max ForteCompletedNCT074275761 country
- Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic SubjectsCompletedNCT06803953Not applicable1 country
- The Incidence of Venous Thromboembolism in Atopic DermatitisCompletedNCT049696531 country
- Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis PatientsCompletedNCT05019209Not applicable1 country
- Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/RhinoconjunctivitisTerminatedNCT04874714Phase 31 country
- Airway Immune Response to Allergens (Use Lay Language Here)Active, not recruitingNCT04619017Phase 11 country
- Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.CompletedNCT01134757Not applicable1 country
- The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving ImmunotherapyStatus unknownNCT05450289Not applicable
- Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority AllergensCompletedNCT04435678Not applicable1 country
- Long-term Effect of a 3-month Supplementation With Holo-BLG on House Dust Mite Induced Allergic RhinoconjunctivitisCompletedNCT048728681 country
- Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic PatientsCompletedNCT04673591Phase 21 country
- Epigenetic Regulation of Exercise Induced AsthmaStatus unknownNCT05174689Not applicable1 country
- Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic RhinoconjunctivitisCompletedNCT044773821 country
- Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated ARCompletedNCT02443805Phase 32 countries
- Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With AsthmaStatus unknownNCT04109534Not applicable1 country
- Biological Standardization of Dermatophagoides Pteronyssinus Allergen ExtractCompletedNCT01821716Phase 21 country
- Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite ExtractWithdrawnNCT00927329Phase 1
- Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic PatientsCompletedNCT03094845Phase 21 country
- A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy TabletCompletedNCT01454544Phase 31 country
- Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic RhinitisCompletedNCT02123316Phase 21 country
- Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic AsthmaCompletedNCT01930461Phase 23 countries
- Role of the Central Nervous System in Allergic RhinitisTerminatedNCT01777464Not applicable1 country
- AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)Status unknownNCT02238353Phase 41 country
- SUBLIVAC FIX Mite Mixture Dose Tolerability StudyCompletedNCT02345278Phase 1/21 country
- Role of Indoor Pollutants on House Dust Mite Allergic AsthmaWithdrawnNCT01019291Not applicable1 country
- Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial AsthmaCompletedNCT00263640Phase 31 country
- Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen ExtractsCompletedNCT01608243Phase 11 country
- ToleroMune House Dust Mite Follow on StudyCompletedNCT01923792
- Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol SupplementsCompletedNCT00466596Phase 11 country
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic RhinoconjunctivitisCompletedNCT00574704Phase 2
- Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic RhinoconjunctivitisCompletedNCT00263549Phase 41 country
- Validation of an Environmental Exposure Chamber for Inhalation Studies With House Dust Mite Allergen in Patients With Allergic RhinitisCompletedNCT01275456Not applicable1 country
- Safety of ToleroMune House Dust Mite (HDM) to Treat House Dust Mite Allergy in HDM Allergic Subjects With RhinoconjunctivitisCompletedNCT01008332Phase 21 country
- A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic RhinoconjunctivitisCompletedNCT00574223Phase 21 country
- Fish Oil and Asthma in House Dust Mite AllergyCompletedNCT00380926Phase 2/3